Laidlaw began coverage on shares of VBI Vaccines Inc. (NASDAQ:VBIV) in a research report report published on Monday. The firm issued a buy rating and a $6.00 target price on the biopharmaceutical company’s stock.

Separately, Ladenburg Thalmann started coverage on VBI Vaccines in a report on Tuesday, July 26th. They set a buy rating on the stock.

Shares of VBI Vaccines (NASDAQ:VBIV) opened at 3.11 on Monday. The firm’s market cap is $112.37 million. The firm’s 50-day moving average price is $3.64 and its 200-day moving average price is $3.81. VBI Vaccines has a one year low of $3.07 and a one year high of $7.80.

A hedge fund recently raised its stake in VBI Vaccines stock. BlackRock Fund Advisors raised its position in shares of VBI Vaccines Inc. (NASDAQ:VBIV) by 1,701.6% during the second quarter, according to its most recent filing with the SEC. The fund owned 44,789 shares of the biopharmaceutical company’s stock after buying an additional 42,303 shares during the period. BlackRock Fund Advisors owned about 0.14% of VBI Vaccines worth $177,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 12.26% of the company’s stock.

About VBI Vaccines

VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.

5 Day Chart for NASDAQ:VBIV

Receive News & Ratings for VBI Vaccines Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines Inc. and related companies with's FREE daily email newsletter.